新华制药：富马酸伏诺拉生化学原料药上市申请获批准

Core Viewpoint - The company has received approval from the National Medical Products Administration for the marketing application of fumaric acid volnorelin, which is primarily used for treating gastroesophageal reflux disease [1] Group 1 - The drug fumaric acid volnorelin has been approved for marketing, indicating a significant milestone for the company [1] - This approval may enhance the company's product portfolio and potentially increase revenue from the treatment of gastroesophageal reflux disease [1]